v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

NCT03447990 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Reduced Ejection Fraction
Dilated Cardiomyopathy

Interventions

DRUG: MYK-491
DRUG: Placebo

Sponsor

Bristol-Myers Squibb